Diamyd, Inc.

8 articles about Diamyd, Inc.

• Diamyd® Phase IIb trial results published in Diabetes Care

  5/21/2021

  Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical's lead drug candidate Diamyd ®  (GAD-alum) in individuals recently diagnosed with type 1 diabetes.

• Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA

  10/15/2019

  The agreement with the Norwegian University of Science and Technology in Trondheim refers to a first, investigator initiated clinical Phase II trial with the diabetes vaccine Diamyd® administered directly into the lymph node in a limited number of patients newly diagnosed with LADA

• Diamyd, Inc. Release: Quarterly Report I 11/12

  1/25/2012

• Prevention Study with Diamyd, Inc.'s Diabetes Vaccine Fully Recruited

  1/9/2012

• Diamyd, Inc. Makes Investment in Time-to-market

  10/1/2009

• Diamyd, Inc. Gets Authorization to Begin Phase III Study in the US

  3/14/2008

• Institutional Investment Of US$ 1.5 M In Diamyd, Inc. At Market Price

  12/19/2006

• Pittsburgh Life Sciences Greenhouse Invests $100,000 In Diamyd, Inc. For The Treatment Of Chronic Pain And Neuropathies

  3/21/2006